|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe largely nonoverlapping genetic determinants in AMPK genes for diabetes-/atherosclerosis-related traits, which reflect the metabolic pathways controlled by the enzyme.
|
31512724 |
2020 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study demonstrated that SIRT1/AMPK and Akt/eNOS signaling pathways are involved in endothelial protection of TASAES against atherosclerotic mice, suggesting that TASAES is a candidate drug for atherosclerosis treatment.
|
30637828 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
VSMC-specific SCAP knockdown decreased the lipid accumulation and intracellular oxidative stress, increased excessive lipid clearance by enhancing lipid autophagy mediated by the reactive oxygen species/AMPK pathway in VSMCs, and consequently alleviated atherosclerosis plaque formation.-Li, D., Chen, A., Lan, T., Zou, Y., Zhao, L., Yang, P., Qu, H., Wei, L., Varghese, Z., Moorhead, J. F., Chen, Y., Ruan, X.
|
30462530 |
2019 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individuals with the rs671 SNP in the gene encoding aldehyde dehydrogenase 2 (ALDH2) are at increased risk of cardiovascular disease (CVD); however, it has been unclear if this mutation contributes to CVD development.In this issue of the JCI, Zhong et al. perform an elegant set of experiments that reveal a pathway wherein the ALDH2 rs671 mutant is phosphorylated by AMPK and translocates to the nucleus where it represses the transcription of a lysosomal H+ pump subunit that is critical for lipid degradation and foam cell formation, as occurs in atherosclerosis.
|
30507608 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this chapter we describe methods that monitor macrophage cholesterol homeostasis such as cholesterol synthesis, uptake, and efflux, all with the use of AMPK activators and potential genetic models that could help shed light on the role of this metabolic regulator in atherosclerosis and other chronic diseases.
|
29480494 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atherosclerosis attenuated vasodilation to cromakalim and the AMPK activator A769662 but not peroxynitrite.
|
28365690 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apocynum leaf extract inhibits the progress of atherosclerosis in rats via the AMPK/mTOR pathway.
|
29441896 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative transcriptomic analysis of mice liver treated with different AMPK activators in a mice model of atherosclerosis.
|
28178661 |
2017 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, AMPK-α2 deficiency abolished the effects of metformin on Drp1 expression, oxidative stress, and atherosclerosis in diabetic ApoE<sup>-/-</sup>/AMPK-α2<sup>-/-</sup> mice, indicating that metformin exerts an antiatherosclerotic action in vivo via the AMPK-mediated blockage of Drp1-mediated mitochondrial fission.
|
27737949 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis.
|
27063143 |
2016 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AMPK-dependent phosphorylation of SREBP may offer therapeutic strategies to combat insulin resistance, dyslipidemia, and atherosclerosis.
|
21459323 |
2011 |